Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134559 · ClinicalTrials.gov registry record · Phase 2
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
A Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma, sponsored by Allison O'Neill, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT04134559: Recruiting Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma, sponsored by Allison O'Neill, MD.
NCT04134559 is a Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma that is actively recruiting participants, run by Allison O'Neill, MD. The registered enrollment target is 18 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04134559, a Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma, is actively recruiting participants, sponsored by Allison O'Neill, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Primary Outcome
irRECIST criteria
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (5)
Massachusetts
- Children's Hospital Boston - Boston
- Dana Farber Cancer Institute - Boston
California
- University of California San Francisco - San Francisco
Ohio
- Cincinnati Children's Medical Center - Cincinnati
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
What NCT04134559 shows while recruiting
NCT04134559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT04134559 lists 5 locations in 4 states (Massachusetts, California, Ohio).
Frequently Asked Questions
What is clinical trial NCT04134559 about?
NCT04134559 is a clinical study titled "Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma". This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
What is the current status of trial NCT04134559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2020-11-01. Estimated completion is 2028-01-01.
What conditions does trial NCT04134559 study?
This clinical trial studies the following conditions: Liver Cancer, Fibrolamellar Carcinoma, Hepatocellular Carcinoma, Childhood, Liver Cancer, Pediatric.
What interventions are being tested in trial NCT04134559?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04134559?
This trial is sponsored by Allison O'Neill, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04134559 being conducted?
This trial has 5 study locations across California, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04134559's enrollment target sits among peer trials
18 65th of 78 higher than 12 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI